Latest News
Featured News
Latest SCOPE data confirm durable improvement
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Select the category
Annual Report 30th April 2022
Modi-1 Phase 1/2 clinical trial open for recruitment
Vaccine Can Induce CD4-Mediated Responses to Homocitrullinated Peptides via Multiple HLA-Types and Confer Anti-Tumor Immunity
Broadening of COVIDITY Phase 1 clinical trial in South Africa
Scancell progresses its new anti-glycan monoclonal antibody (mAb) platform GlyMab™
PAD-2- mediated citrullination of nucleophosmin provides an effective target for tumor immunotherapy
An Immunohistochemical Evaluation of Tumor-Associated Glycans and Mucins as Targets for Molecular Imaging of Pancreatic Ductal Adenocarcinoma
Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging
Update on COVIDITY Phase 1 clinical trial in South Africa
Interim Results for the 6 months ended 31 October 2021
Interim Report 31st October 2021
Annual Report 30th April 2021
No results found.
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.